# Techno Science

> Techno Science is a VC fund in Kashiwa backing Therapeutics, Medical and Health Care. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Kashiwa, Japan
- Total investments: 4
- Last investment: May 2026
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://www.t-science.co.jp/

Techno Science is a VC fund in Kashiwa focused on Therapeutics and Medical. Techno Science primarily engages in the technology development business.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Therapeutics | 2 | 50% |
| Medical | 1 | 25% |
| Health Care | 1 | 25% |
| Biotechnology | 1 | 25% |
| Manufacturing | 1 | 25% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 25% |
| Series B | 1 | 25% |
| Series D | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Periotherapia | Periotherapia is a Drug discovery business with triple negative breast cancer as the first indication. Periotherapia aims to selectively inhibit only ASV that is involved in pathogenesis without inhibiting physiological ASV in chronic diseases such as cancer, heart failure, arteriosclerosis, renal failure, and diabetic retinopathy. is. | $3.6M | Series D | May 26, 2026 |  |
| Celaid Therapeutics | Celaid Therapeutics develops technologies and products based on hematopoietic stem cell (HSC) expansion and gene-augmented therapies. The company operates a platform that enables in-vitro propagation of human HSCs without relying on animal-derived components, facilitating scalability, consistency, and cost control. It applies this platform acrossworkflows, including donor/patient cell collection, HSC expansion, cell processing, and gene editing to deliver cell therapy products. Celaid advances pipelines in areas such as blood cancers, genetic disorders, and rare hematologic diseases. Through partnerships and internal research, it seeks to support both reagent/media supply and therapeutic development around HSC-based regenerative medicine. | $3.6M | Series B | Oct 07, 2025 |  |
| Celaid Therapeutics | Celaid Therapeutics develops technologies and products based on hematopoietic stem cell (HSC) expansion and gene-augmented therapies. The company operates a platform that enables in-vitro propagation of human HSCs without relying on animal-derived components, facilitating scalability, consistency, and cost control. It applies this platform acrossworkflows, including donor/patient cell collection, HSC expansion, cell processing, and gene editing to deliver cell therapy products. Celaid advances pipelines in areas such as blood cancers, genetic disorders, and rare hematologic diseases. Through partnerships and internal research, it seeks to support both reagent/media supply and therapeutic development around HSC-based regenerative medicine. | $3M | Series A | May 08, 2024 |  |
| Celaid Therapeutics | Celaid Therapeutics develops technologies and products based on hematopoietic stem cell (HSC) expansion and gene-augmented therapies. The company operates a platform that enables in-vitro propagation of human HSCs without relying on animal-derived components, facilitating scalability, consistency, and cost control. It applies this platform acrossworkflows, including donor/patient cell collection, HSC expansion, cell processing, and gene editing to deliver cell therapy products. Celaid advances pipelines in areas such as blood cancers, genetic disorders, and rare hematologic diseases. Through partnerships and internal research, it seeks to support both reagent/media supply and therapeutic development around HSC-based regenerative medicine. | $3.4M | Series A | Oct 25, 2022 |  |

4 of 4 investments shown.

## Co-investors
- [UTEC - The University of Tokyo Edge Capital Partners](https://shizune.co/investors/profile/utec) — VC Fund, 3 deals together
- [Joyo Capital Partners](https://shizune.co/investors/profile/joyo-capital-partners) — VC Fund, 2 deals together
- [Osaka University Venture Capital](https://shizune.co/investors/profile/osaka-university-venture-capital) — VC Fund, 2 deals together
- [Tsukuba Institute of Research](https://shizune.co/investors/profile/tsukuba-institute-of-research) — VC Fund, 2 deals together
- [Mitsubishi UFJ Capital](https://shizune.co/investors/profile/mitsubishi-ufj-capital) — VC Fund, 1 deal together
- [SBI Group](https://shizune.co/investors/profile/sbi-group) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Mitsubishi UFJ Capital](https://shizune.co/investors/profile/mitsubishi-ufj-capital) — VC Fund
- [SMBC Venture Capital](https://shizune.co/investors/profile/smbc-venture-capital) — VC Fund
- [Mizuho Capital](https://shizune.co/investors/profile/mizuho-capital) — VC Fund

## Featured in investor lists
- [Biotechnology VC Funds in Japan](https://shizune.co/investors/biotechnology-vc-funds-japan)

## FAQ

### What does Techno Science invest in?

Techno Science invests primarily in Therapeutics, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 4 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Techno Science last invest?

The most recent investment recorded for Techno Science closed in May 2026. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co